The trial evaluates liraglutide, a GLP-1 receptor agonist, against sulphonylurea in combination with metformin for managing Type 2 Diabetes Mellitus (T2DM) during Ramadan fasting. Given the increasing prevalence of diabetes in Muslim populations, particularly in Africa and Asia, successful outcomes could enhance liraglutide's market position against established therapies like sulphonylureas. The results may support expanded indications for liraglutide, potentially increasing its market share in diabetes management. Competitive implications include the need for Novo Nordisk to monitor responses from other diabetes therapies, particularly those targeting fasting-related glycemic control. Diligence should focus on the safety profile and patient adherence during fasting periods, which could influence prescribing patterns.